|
| 36111443 | NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab. | J Surg Oncol | 2022 |
| 32835356 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34â¿¿640 Patients in the ACCENT Database. | J Natl Cancer Inst | 2021 |
| 34405233 | Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. | J Natl Cancer Inst | 2021 |
| 33356421 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. | J Clin Oncol | 2021 |
| 32692071 | Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology. | Dis Colon Rectum | 2020 |
| 29905379 | Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. | Am J Hematol | 2018 |
| 27468630 | Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. | J Geriatr Oncol | 2016 |
| 27270348 | Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. | JAMA Oncol | 2016 |
| 25595934 | Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. | Ann Oncol | 2015 |
| 26374429 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. | J Natl Cancer Inst | 2015 |
| 24957075 | A new predictive molecular marker for cetuximab benefit in rectal cancer? | J Natl Cancer Inst | 2014 |
| 25456367 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. | Lancet Oncol | 2014 |
| 24799484 | Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. | J Clin Oncol | 2014 |
| 23310947 | Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. | Cancer | 2013 |
| 24220557 | Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. | J Clin Oncol | 2013 |
| 23821759 | Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. | J Natl Cancer Inst | 2013 |
| 23980089 | Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. | J Clin Oncol | 2013 |
| 23733765 | Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. | J Clin Oncol | 2013 |
| 23810482 | The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. | Clin Colorectal Cancer | 2013 |
| 23385733 | Innovative estimation of survival using log-normal survival modelling on ACCENT database. | Br J Cancer | 2013 |
| 23233715 | Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. | J Clin Oncol | 2013 |
| 21729678 | Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. | Clin Colorectal Cancer | 2012 |
| 23002390 | Gene Signatures in Stage II Colon Cancer: A Clinical Review. | Curr Colorectal Cancer Rep | 2012 |
| 23045248 | Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. | Clin Cancer Res | 2012 |
| 22869888 | Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. | J Clin Oncol | 2012 |
| 22614981 | Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. | J Clin Oncol | 2012 |
| 20940184 | Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. | J Clin Oncol | 2011 |
| 21997132 | Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. | J Natl Cancer Inst | 2011 |
| 21859995 | Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. | J Clin Oncol | 2011 |
| 21365628 | Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. | Cancer | 2011 |
| 21452066 | Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). | Ann Surg Oncol | 2011 |
| 20048179 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. | J Clin Oncol | 2010 |
| 20679606 | Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. | J Clin Oncol | 2010 |
| 20186699 | Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. | Cancer | 2010 |
| 20215553 | Obesity is an independent prognostic variable in colon cancer survivors. | Clin Cancer Res | 2010 |
| 20406942 | Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. | J Clin Oncol | 2010 |
| 20008641 | Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. | J Clin Oncol | 2010 |
| 19997103 | Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. | Br J Cancer | 2010 |
| 19224842 | The marriage of growth factor inhibitors and chemotherapy: bliss or bust? | J Clin Oncol | 2009 |
| 19739269 | Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. | Clin Colorectal Cancer | 2009 |
| 19770376 | Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. | J Clin Oncol | 2009 |
| 19423501 | Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. | Clin Colorectal Cancer | 2009 |
| 19414682 | Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. | J Clin Oncol | 2009 |
| 19414665 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. | J Clin Oncol | 2009 |
| 19451420 | Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. | J Clin Oncol | 2009 |
| 19124803 | Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. | J Clin Oncol | 2009 |
| 18445840 | Potential regional differences for the tolerability profiles of fluoropyrimidines. | J Clin Oncol | 2008 |
| 18794091 | Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. | Clin Cancer Res | 2008 |
| 18798075 | FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. | Cancer Invest | 2008 |
| 18929150 | The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. | Semin Oncol | 2008 |